This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622 (olesoxime) in healthy participants.

Inclusion Criteria:

• Body mass index (BMI) 20.0 to 28.0 kilograms per meter-squared (kg/m^2) and body weight at least 60 kilograms (kg)
• Fitzpatrick skin type less than (<) 4
• Good health according to medical history, physical examination, laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG)
• Negative urine test for drugs of abuse
• Negative alcohol breath test
• Negative tests for hepatitis or human immunodeficiency virus (HIV)
• Use of effective contraception during and for 3 months beyond study participant, among sexually active non-vasectomized participants with females partners of childbearing potential

Exclusion Criteria:

• Concomitant or recent medication use within 2 weeks prior to Day 1, except for paracetamol
• Use of enzyme-inducing drugs within 2 months prior to Day 1
• Any medical condition that may alter the pharmacokinetics of olesoxime or affect interpretation of study results
• Irregular bowel movements
• Drug addiction or alcoholism
• Use of nicotine products
• Participation in another clinical study within 12 weeks prior to Day 1
• Exposure to ionizing radiation within one year prior to Day 1